Axa
ALDR

Axa’s Alder Biopharmaceuticals ALDR Stock Holding History

Axa’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-222,600
Closed -$2.62M – 1384
2019
Q2 		$2.62M Buy
222,600
+139,900
+169% +$1.69M 0.01% 802
2019
Q1 		$1.13M Buy
82,700
+18,700
+29% +$242K ﹤0.01% 956
2018
Q4 		$656K Buy
+64,000
New +$819K ﹤0.01% 1043
2018
Q3 		– Sell
-19,700
Closed -$311K – 1420
2018
Q2 		$311K Sell
19,700
-538,209
-96% -$8.18M ﹤0.01% 1222
2018
Q1 		$7.08M Sell
557,909
-529,300
-49% -$7.66M 0.03% 552
2017
Q4 		$12.4M Buy
1,087,209
+95,126
+10% +$1.06M 0.05% 396
2017
Q3 		$12.2M Buy
992,083
+661,253
+200% +$6.89M 0.05% 385
2017
Q2 		$3.79M Sell
330,830
-12,363
-4% -$229K 0.02% 666
2017
Q1 		$7.14M Buy
343,193
+76,435
+29% +$1.69M 0.03% 515
2016
Q4 		$5.55M Buy
266,758
+5,068
+2% +$132K 0.03% 549
2016
Q3 		$8.58M Sell
261,690
-24,930
-9% -$759K 0.04% 444
2016
Q2 		$7.16M Buy
286,620
+33,441
+13% +$905K 0.03% 480
2016
Q1 		$6.2M Sell
253,179
-4,090
-2% -$94.7K 0.03% 500
2015
Q4 		$8.5M Buy
257,269
+12,760
+5% +$431K 0.04% 431
2015
Q3 		$8.01M Buy
244,509
+55,074
+29% +$2.34M 0.03% 438
2015
Q2 		$10M Buy
+189,435
New +$6.89M 0.04% 419

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $494M AUM 23.45% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Axa's ALDR Position: Q3 2019 in Review

Axa sold out of Alder Biopharmaceuticals (ALDR) in Q3 2019, closing a stake of 222,600 shares — an estimated $2.62M sold.

Axa first reported a position in ALDR in Q2 2015 and held it in 16 quarters. The position peaked at $12.4M in Q4 2017. 143 funds tracked by Wall St. Rank hold ALDR as of Q3 2019.

  • Axa reported no remaining Alder Biopharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Axa sold 222,600 Alder Biopharmaceuticals shares in Q3 2019, an estimated $2.62M.
  • Axa first reported a position in Alder Biopharmaceuticals in Q2 2015 and held it in 16 quarters.
  • Axa's Alder Biopharmaceuticals position peaked at $12.4M in Q4 2017.
  • 143 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2019.

Based on Axa's 13F filing for Q3 2019, filed 14 Nov 2019.